Owing to increased early detection with cancer screening programs and advances in systemic treatment such as curative surgery, chemotherapy, vascular endothelial growth factor (VEGF)-targeted treatment (e.g., bevacizumab, cetuximab), and BRAF V600E/K-mutant targeted therapy, more patients survive after CRC treatment [4, 5]. This evidence concerns the gene VEGFA and cancer.